For the quarter ending 2026-03-31, AVLN had $39,995K increase in cash & cash equivalents over the period. -$30,209K in free cash flow.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -26,869 |
| Depreciation | 63 |
| Non-cash operating lease expense | 109 |
| Stock-based compensation expense | 1,193 |
| Amortization and accretion of premiums/discounts on marketable securities | 237 |
| Amortization of debt discount and deferred financing costs | 5 |
| Prepaid expenses and other current assets | 508 |
| Other assets | 0 |
| Accounts payable | -1,113 |
| Accrued liabilities | -2,464 |
| Operating lease liability | -70 |
| Net cash used in operating activities | -29,891 |
| Purchases of property and equipment | 318 |
| Purchases of marketable securities | 0 |
| Proceeds from sale of marketable securities | 26,342 |
| Maturities of marketable securities | 29,000 |
| Net cash provided by investing activities | 55,024 |
| Proceeds from the exercise of stock options | 25 |
| Proceeds from term loan | 15,000 |
| Payments of issuance costs associated with term loan | 163 |
| Net cash provided by financing activities | 14,862 |
| Increase (decrease) in cash and cash equivalents | 39,995 |
| Beginning of period | 52,315 |
| End of period | 92,310 |
Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. (AVLN)